Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
Reuters
Published Oct 20, 2021 07:09AM ET
(Reuters) - Cigna Corp (NYSE:CI)'s pharmacy benefit unit said on Wednesday it will prefer Viatris Inc and Biocon Biologics Ltd's insulin drug Semglee, a cheaper alternative to Sanofi (NASDAQ:SNY) SA's Lantus, on the list of medicines it reimburses on behalf of health insurers.
The unit, Express Scripts (NASDAQ:ESRX), said it expects cost savings of $20 million in 2022 by preferring the Semglee injection.
Drugmakers such as Eli Lilly (NYSE:LLY), Sanofi and Novo Nordisk (NYSE:NVO) have been under pressure to make their insulin products more affordable amid heavy criticism from lawmakers and patients in a country with a diabetes problem.
One in 10 Americans, or 34 million people, have diabetes, and researchers have found significant increases in the disease among both sexes and across racial and ethnic groups.
Semglee won U.S. approval in July as a biosimilar that can be used instead of Lantus without a physician's intervention.
Sales of Lantus, once Sanofi's top insulin product, have declined since its U.S. patent expired in 2015.
Biosimilars, cheaper copies of high-priced drugs, can help reduce costs, both through direct savings and competition that encourages lower prices, Express Scripts said.
Pharmacy benefit managers such as Express Scripts and CVS Health Corp (NYSE:CVS) help health insurers negotiate better prices from drugmakers and also draw up "formularies", or lists of drugs reimbursed by the insurers they work for.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.